Overview

Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, 3-period 3-treatment crossover followed by a 2-period 2-treatment crossover, phase 2 study in patients with documented hyperuricemia to evaluate the effect of tranilast on allopurinol pharmacokinetics (PK) and pharmacodynamics (PD) and to evaluate the effect of allopurinol on tranilast PK and PD as measured by reduction in serum uric acid levels.
Phase:
Phase 2
Details
Lead Sponsor:
Nuon Therapeutics, Inc.
Treatments:
Allopurinol
Tranilast